Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Shares Sold by PFG Investments LLC

PFG Investments LLC cut its holdings in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) by 12.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,000 shares of the company's stock after selling 3,700 shares during the quarter. PFG Investments LLC's holdings in Verona Pharma PLC American Depositary Share were worth $1,651,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in Verona Pharma PLC American Depositary Share during the fourth quarter worth about $720,000. Wells Fargo & Company MN increased its holdings in shares of Verona Pharma PLC American Depositary Share by 27.2% during the 4th quarter. Wells Fargo & Company MN now owns 67,126 shares of the company's stock worth $3,117,000 after buying an additional 14,362 shares during the last quarter. Northern Trust Corp acquired a new stake in shares of Verona Pharma PLC American Depositary Share during the 4th quarter worth approximately $362,000. Cetera Investment Advisers increased its holdings in shares of Verona Pharma PLC American Depositary Share by 113.4% during the 4th quarter. Cetera Investment Advisers now owns 23,265 shares of the company's stock worth $1,080,000 after buying an additional 12,362 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of Verona Pharma PLC American Depositary Share during the 4th quarter worth approximately $285,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Cowen assumed coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, April 28th. They set a "buy" rating for the company. Cantor Fitzgerald raised their price target on shares of Verona Pharma PLC American Depositary Share from $90.00 to $100.00 and gave the stock an "overweight" rating in a report on Wednesday, June 11th. HC Wainwright raised their price target on shares of Verona Pharma PLC American Depositary Share from $85.00 to $90.00 and gave the stock a "buy" rating in a report on Monday, June 2nd. TD Cowen started coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, April 28th. They issued a "buy" rating and a $100.00 target price for the company. Finally, Jefferies Financial Group lifted their target price on shares of Verona Pharma PLC American Depositary Share from $95.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $94.56.

Insiders Place Their Bets

In other Verona Pharma PLC American Depositary Share news, General Counsel Andrew Fisher sold 80,000 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $11.53, for a total value of $922,400.00. Following the completion of the transaction, the general counsel now owns 359,999 shares in the company, valued at $4,150,788.47. The trade was a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO David Zaccardelli sold 90,360 shares of the business's stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $8.98, for a total transaction of $811,432.80. Following the completion of the transaction, the chief executive officer now owns 14,377,176 shares of the company's stock, valued at approximately $129,107,040.48. This trade represents a 0.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,965,800 shares of company stock worth $20,056,881 over the last 90 days. Corporate insiders own 4.80% of the company's stock.

Verona Pharma PLC American Depositary Share Stock Performance

NASDAQ:VRNA opened at $94.32 on Friday. The company has a fifty day simple moving average of $74.68 and a two-hundred day simple moving average of $62.24. The company has a market cap of $8.03 billion, a price-to-earnings ratio of -47.16 and a beta of 0.21. The company has a quick ratio of 8.73, a current ratio of 8.86 and a debt-to-equity ratio of 1.07. Verona Pharma PLC American Depositary Share has a 52 week low of $14.14 and a 52 week high of $94.45.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.49. The business had revenue of $98.65 million during the quarter, compared to analyst estimates of $41.47 million. As a group, equities analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.